Takeda Pharmaceutical Co. Ltd. Makes New Investment in Shattuck Labs, Inc. (NASDAQ:STTK)

Takeda Pharmaceutical Co. Ltd. acquired a new stake in Shattuck Labs, Inc. (NASDAQ:STTK) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 515,619 shares of the company’s stock, valued at approximately $624,000. Shattuck Labs accounts for about 2.3% of Takeda Pharmaceutical Co. Ltd.’s investment portfolio, making the stock its 5th biggest holding. Takeda Pharmaceutical Co. Ltd. owned 1.08% of Shattuck Labs at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its position in Shattuck Labs by 63.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock valued at $96,000 after buying an additional 10,667 shares during the period. Geode Capital Management LLC boosted its holdings in Shattuck Labs by 0.9% in the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock valued at $3,184,000 after purchasing an additional 8,133 shares during the period. MetLife Investment Management LLC grew its stake in Shattuck Labs by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares in the last quarter. State Street Corp grew its stake in Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after purchasing an additional 55,579 shares in the last quarter. Finally, Barclays PLC increased its holdings in Shattuck Labs by 299.5% during the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock worth $189,000 after purchasing an additional 40,717 shares during the period. Institutional investors and hedge funds own 58.74% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on STTK. Leerink Partnrs upgraded Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Leerink Partners assumed coverage on shares of Shattuck Labs in a report on Monday, March 17th. They set an “outperform” rating and a $4.00 price target for the company. Four research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.50.

Shattuck Labs Stock Performance

Shares of NASDAQ STTK opened at $1.18 on Thursday. The stock’s 50-day simple moving average is $1.24 and its 200-day simple moving average is $1.51. The firm has a market capitalization of $56.33 million, a PE ratio of -0.77 and a beta of 1.66. Shattuck Labs, Inc. has a fifty-two week low of $0.94 and a fifty-two week high of $11.76.

Shattuck Labs Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.